Business Wire

3M Enhances the Emphaze™ AEX Hybrid Purifier

Del

Achieving high product purity early in the manufacturing process and improving efficiency and economics is important to biopharmaceutical manufacturers. Increasing removal of impurities like DNA and HCP during clarification improves the performance of downstream capture and polishing steps. The 3M™ Emphaze™ AEX Hybrid Purifier meet these challenges through reduction of cell debris, DNA and HCP at clarification to help improve downstream process steps. The new Emphaze capsules are sterilization/sanitization compatible and can be used across various aqueous based biopharmaceutical processes, including vaccine purification. Additionally, the improved Emphaze AEX Hybrid Purifier products now feature two new laboratory capsules and one scale-up capsule that allows evaluations at laboratory and scale-up volumes.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180905005283/en/

The 3M™ Emphaze™ AEX Hybrid Purifier (Photo: 3M)

The 3M™ Emphaze™ AEX Hybrid Purifier (Photo: 3M)

“Customer input is critical in evaluating the performance and effectiveness of any product to maximize performance,” said Himanshu Nivsarkar, Global Marketing Manager, 3M Separation and Purification Sciences Division. “With the Emphaze AEX Hybrid Purifier, customers experience benefits in typical monoclonal antibody purification processes, including nominal 30% HCP and greater than 4 log DNA reduction. It has a consistent output turbidity (<5 NTU) leading to potential downsizing of the sterilizing grade membrane and increased product purity post-protein A. This also reduces turbidity post viral inactivation/neutralization step leading to a lower impurities load on the downstream AEX column, thus allowing customers to optimize their processes.”

Emphaze AEX Hybrid Purifier products are synthetic multi-mechanism single-use purifier products used for biopharmaceutical clarification. They deliver consistent, high purity clarified process fluid by removing soluble and insoluble impurities, such as DNA, HCP, and cell debris, through a combination of chromatographic and size exclusion mechanisms. Emphaze AEX Hybrid Purifier products combine three unique 3M technologies — advanced polymer materials, fine fiber nonwovens, and membranes — to deliver a synthetic clarifying product line containing a novel anion exchange nonwoven media and a fine particle, reduction membrane.

For more information, visit 3m.com/bioprocessing

About 3M

At 3M, we apply science in collaborative ways to improve lives daily. With $32 billion in sales, our 91,000 employees connect with customers all around the world. Learn more about 3M’s creative solutions to the world’s problems at www.3M.com or on Twitter @3M or @3MNews.

3M and Emphaze are trademarks of 3M Company.

Product Bulletin

Contact information

For 3M
Emily Sudlow, 612-342-9893
Karwoski & Courage Public Relations
emily.sudlow@creativepr.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Janssen Seeks Expanded Use of IMBRUVICA®▼ (ibrutinib) in Two Indications in Europe14.11.2018 14:23Pressemelding

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of two Type II variation applications to the European Medicines Agency (EMA) seeking approval for the expanded use of IMBRUVICA® (ibrutinib). One application seeks to include use of ibrutinib in combination with obinutuzumab in previously untreated adults with chronic lymphocytic leukaemia (CLL) and to add long-term follow-up data from the existing label studies RESONATETM (PCYC-1112) and RESONATETM-2 (PCYC-1115). The second is for use of ibrutinib plus rituximab for the treatment of previously untreated and relapsed/refractory adults with Waldenström's macroglobulinemia (WM). “Today’s news brings us one step closer to potentially offering ibrutinib in new combinations for patients where unmet needs still persist,” said Dr. Catherine Taylor, Haematology Therapy Area Lead, Europe, Middle East and Africa (EMEA), Janssen-Cilag Limited. “Ibrutinib continues to demonstrate clinical benefit over the long

ResMed Completes Acquisition of MatrixCare14.11.2018 14:05Pressemelding

ResMed (NYSE: RMD) (ASX: RMD), a leader in cloud-connected medical devices and out-of-hospital software-as-a-service (SaaS) business solutions, today announced it has completed its $750 million acquisition of Minnesota-based MatrixCare, a leader in software solutions for more than 15,000 providers across skilled nursing, life plan communities, senior living and private duty. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181114005282/en/ These care settings are complementary to ResMed’s other SaaS offerings in home medical equipment, home health and hospice, delivered through Brightree and HEALTHCAREfirst, acquired by ResMed in April 2016 and July 2018, respectively. ResMed will drive an integrated ecosystem of solutions across these platforms to maintain single-patient records across multiple care settings, generate analytics and insights that can be applied to individuals and whole populations, and streamline processes acr

REPLY: The Board of Directors Approves the Quarterly Financial Report as of 30 September 201814.11.2018 13:30Pressemelding

Today, the Board of Directors of Reply [MTA, STAR: REY] approved the results as at 30 September 2018. In the first nine months of the year, the Group has recorded a consolidated turnover of €754.4 million, with an increase of 15.8% compared to €651.3 million at September 2017. Consolidated EBITDA to September was €101.2 million (€89.8 million at September 2017) with an EBIT of €91.4 million (€81.7 million at September 2017). Pre-tax profit amounted to €96.3 million, which represents an increase of 22.4% compared to the same period of 2017. For the third quarter of 2018 (July-September), the Group registered a consolidated turnover of €256.3 million (€209.7 million in 2017), an EBITDA of €32.9 million (€28.0 million in 2017), an EBIT of €29.3 million (€24.7 million in 2017) and a pre-tax profit of €32.1 million (25.3 million in 2017). As at 30 September 2018, the Group's net financial position was positive for €56.3 million, improving compared to €50.2 million registered on June 30, 201

Blackjack Booster Lands at Intertops Poker14.11.2018 13:20Pressemelding

Intertops Poker is boosting player winnings this weekend with an extra 10% on the Lucktap games Blackjack, Face Up 21, Double Draw Blackjack and Perfect Pairs Blackjack. The promotion is being offered exclusively through the Intertops Poker software, and will run from Friday 16th November to Sunday 18th November. To access the promotion, players log into the Intertops Poker software and click the Casino tab in the top right hand corner. They then chose from one of the Lucktap games (Blackjack, Face Up 21, Double Draw Blackjack and Perfect Pairs Blackjack) offered and any winning bets will be increased by 10%. The additional 10% winnings will be shown as a bonus balance and will be released once the x15 wagering requirement has been met. The maximum prize that can be won is $250. The poker manager at Intertops Poker, said: “Here at Intertops Poker we are always looking to provide our players with even more value, which is why we are boosting all winnings on our Lucktap games by 10% this

Corsearch Announces Acquisition of Yellow Brand Protection14.11.2018 13:00Pressemelding

Corsearch Inc. and its related entities, a trademark and domain solutions leader, is pleased to announce the acquisition of Yellow Brand Protection AB of Sweden, a leading global provider of online anti-counterfeiting and brand protection services. The acquisition, effective immediately, solidifies and further expands Corsearch’s full service brand protection offering for clients and brands globally . The facts speak for themselves in this industry – In 2018, online sales will approach $3 trillion U.S. Dollars, with one in four online purchases involving pirated goods. Online IP infringement is a continued and increasingly expanding challenge for all brands, as e-commerce growth continues at record speed and digital marketing becomes a core business strategy. Corsearch, founded in 1949, provides industry-leading brand establishment and protection services for trademark and brand professionals in over 60 countries on five continents. Yellow Brand Protection, founded in 2010, provides br

PEI-Genesis Approved as Category C Distributor for All Conesys Product Lines14.11.2018 11:15Pressemelding

PEI-Genesis, the world’s fastest assembler of precision connectors, has been approved as a Category C Distributor for all Conesys product lines. PEI-Genesis will be assembling all government approved Mil-Circular connector product lines manufactured by Conesys at the company’s South Bend, IN facility. “The addition of Conesys Mil-Circular connectors gives global, value-added access to all customers and adds to the breadth of Conesys’ offerings,” said Peter Austin, PEI-Genesis’s Senior Vice President of Manufacturing, Product Management, Marketing, & Training. “The new partnership will give Conesys access to our award-winning service and largest available-to-sell connector inventory.” PEI-Genesis has inventory to assemble Conesys connectors now, and will be able to assemble over 50,000 military connector part numbers from Conesys inventory very soon. Product families being assembled by PEI-Genesis for Conesys include the MIL-DTL-38999, MIL-DTL-26482, MIL-DTL-83723, and MIL-DTL-26500. “W